Abstract 5643
Background
Survival of patients with solid cancer improved over the last decade. Whether this translates in survival advances when they become critically ill is uncertain. We sought to determine trends in survival over time in critically ill patients with solid tumors.
Methods
Retrospective single center cohort of patients with solid tumors admitted to ICU over a 10-year period. Factors independently associated with day-30 and 1-year mortality after ICU discharge were identified.
Results
A total of 669 patients were admitted. Primary site of cancer was lung (21%), digestive (20%) and breast cancer (19%); 335 patients (54%) had metastasis. A decision to withhold/withdraw life sustaining therapies was implemented in 158 (25%) patients. ICU, Day-30 and one-year mortality were 23%, 35% and 41%. Among the 484 (77%) ICU survivors, 248 (39%) actually underwent an oncologic treatment following ICU discharge. Factors associated with day-30 mortality included: the period of ICU admission (HR = 0.7, p = 0.03 after 2010 vs before 2010), poor performance status (>2) (HR = 1.4, p = 0.03), metastatic stage of cancer (vs localized cancer) (HR = 2.1, p = 0.002), need for mechanical ventilation (HR = 4.5, p < 0.0001, or vasopressors (HR = 2.3, p = 0.0003). Decisions for forgo life-sustaining therapy in ICU were also associated with day-30 mortality (HR = 3.3, p < 0.0001). Factors associated with 1-year mortality included ICU admission after 2010 (HR 0.5, p < 0.001), locally advanced (HR = 1.8, p = 0.002) or metastatic cancer (HR = 2.2, p = 0.002), poor performance status (HR = 1.5, p = 0.01), newly diagnosed cancer at ICU admission (HR = 2.0, p = 0.003) the inability to receive a cancer treatment after ICU discharge (HR = 5.3, p < 0.001) and decisions to forgo life-sustaining therapy throughout ICU stay (HR = 2.3, p < 0.001).
Conclusions
In critically-ill oncology patients, survival improves over time. Tumor staging and performance status impact on both short-term and long-term mortality suggesting that the goals of care should be better fine-tuned in the future. Most importantly, patient’s ability to receive cancer treatment and oncologist willingness to provide optimal cancer management are major determinants of 1-year mortality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
E. Azoulay.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1735 - mTOR inhibition in the treatment of resistant breast cancer
Presenter: María Rodriguez
Session: Poster Display session 1
Resources:
Abstract
6068 - Study of Photodynamic therapy in vitro
Presenter: Irene Jiménez Munguía
Session: Poster Display session 1
Resources:
Abstract
3011 - The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models
Presenter: Neil Conlon
Session: Poster Display session 1
Resources:
Abstract
2644 - Novel HDACi, MHY446, induces apoptosis via regulation of mitochondria-endoplasmic reticulum interaction in HCT116 human colorectal cancer cells
Presenter: Nam Deuk Kim
Session: Poster Display session 1
Resources:
Abstract
3085 - Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer
Presenter: Davide Ciardiello
Session: Poster Display session 1
Resources:
Abstract
1314 - PARP inhibition enhances cisplatin sensitivity in cervical cancer by modulating β-catenin signaling
Presenter: Minakshi Mann
Session: Poster Display session 1
Resources:
Abstract
2417 - Synergistic effect of DSF combined treatment with cisplatin in atypical teratoid/rhabdoid tumors (AT/RT)
Presenter: Seung Ah Choi
Session: Poster Display session 1
Resources:
Abstract
1149 - Reactive oxygen species induced by OSU-A9 inhibit the growth of duodenal cancer and gastric cancer cells through dephosphorylating intranuclear pyruvate kinase muscle isozyme M2
Presenter: Li-Yuan Bai
Session: Poster Display session 1
Resources:
Abstract
1862 - New therapy for intrahepatic cholangiocarcinoma targeted to cancer associated fibroblasts
Presenter: Takahiro Yamanaka
Session: Poster Display session 1
Resources:
Abstract
782 - Macrophage-cancer cell fusion is mediated by Phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation
Presenter: Ivan Shabo
Session: Poster Display session 1
Resources:
Abstract